Zepbound for Sleep Apnea: Approval, Dose, Trial Results, and Cost
The FDA approved Zepbound (tirzepatide) on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. One-year trials showed 25 to 29 fewer breathing disruptions per hour and 18% to 20% weight loss; the trials tested it with and without PAP therapy, not stopping PAP.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
On December 20, 2024, the FDA approved Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity [2, 3]. Lilly billed it as the first and only prescription medicine for that use, and it became Zepbound’s second US approval after its November 2023 approval for weight management [2]. The approval is specifically for adults who have both conditions — moderate-to-severe OSA and obesity — and the label says it should be used alongside a reduced-calorie diet and increased physical activity [1, 2].
The approval does not settle the question of CPAP. The trials behind it tested Zepbound in people who could not or would not use PAP therapy, and separately in people who stayed on PAP therapy throughout the study [2].
What exactly did the FDA approve, and when?
The FDA approved the new indication on December 20, 2024, through a supplement to Zepbound’s existing New Drug Application (NDA 217806), classified as “Efficacy-New Indication” with an action date of 12/20/2024 [3]. Eli Lilly billed it as the first and only prescription medicine for moderate-to-severe OSA in adults with obesity [2].
Zepbound is a dual GIP and GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor [1, 2]. The tirzepatide molecule was first approved in the United States in 2022 [1]. Zepbound’s first US indication, approved in November 2023, covers reducing excess body weight and keeping it off long term in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition [2].
The exact label wording for the sleep apnea indication is: “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity,” in combination with a reduced-calorie diet and increased physical activity [1]. The label also carries a limitation of use: coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended [1].
Who qualifies for Zepbound for sleep apnea?
The label population is adults who have both moderate-to-severe OSA and obesity, and the indication requires use with a reduced-calorie diet and increased physical activity [1]. It covers obstructive sleep apnea — the kind caused by complete or partial collapse of the upper airway during sleep — not central sleep apnea [2].
It is not approved for children. Lilly states it is not known whether Zepbound is safe and effective for use in children [2].
A diagnosis comes first. The indication applies to adults with moderate-to-severe OSA, and Lilly notes that many cases of OSA go undiagnosed and untreated [2]. The label wording — “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity” — is the boundary of who the approval covers [1].
What is OSA, and what does the AHI measure?
OSA is a sleep-related breathing disorder in which the upper airway collapses completely or partially during sleep [2]. That collapse causes apnea (a pause in breathing) or hypopnea (shallow breathing), which can drop oxygen saturation or wake the sleeper [2].
The trials measured results using the apnea-hypopnea index (AHI). The primary endpoint of the SURMOUNT-OSA trials was the change in AHI from baseline at 52 weeks [2].
Common symptoms include snoring, fatigue, excessive daytime sleepiness, and disrupted sleep — symptoms Lilly says make this serious condition easily overlooked [2].
What did the SURMOUNT-OSA trials show?
The approval was based on the SURMOUNT-OSA phase 3 trials (NCT05412004), a multi-center, randomized, double-blind, parallel, placebo master protocol [2]. The two studies randomized 469 participants across the US, Australia, Brazil, China, Czechia, Germany, Japan, Mexico, and Taiwan, in a 1:1 ratio to Zepbound or placebo [2].
Study 1 enrolled adults with moderate-to-severe OSA and obesity who were unable or unwilling to use PAP therapy. Study 2 enrolled adults who were on PAP and planned to stay on it for the whole trial [2]. Both ran for 52 weeks — one year [2].
In the trial, dosing started at 2.5 mg and increased by 2.5 mg every four weeks until each participant reached a maximum tolerated dose of 10 mg or 15 mg. Those who tolerated 15 mg stayed on 15 mg; those who tolerated 10 mg but not 15 mg stayed on 10 mg [2].
The headline results at one year:
| Result at 52 weeks | Zepbound | Placebo |
|---|---|---|
| Breathing disruptions per hour, not on PAP (Study 1) | 25 fewer | 5 fewer [2] |
| Breathing disruptions per hour, on PAP (Study 2) | 29 fewer | 6 fewer [2] |
| Remission or mild, non-symptomatic OSA, not on PAP | 42% | 16% [2] |
| Remission or mild, non-symptomatic OSA, on PAP | 50% | 14% [2] |
| Weight loss, not on PAP | 45 lbs (18%) | 4 lbs (2%) [2] |
| Weight loss, on PAP | 50 lbs (20%) | 6 lbs (2%) [2] |
Lilly framed the no-PAP result as Zepbound being about five times more effective than placebo at reducing breathing disruptions [2]. Its summary line for the trials overall: averaging up to 20% weight loss and at least 25 fewer breathing interruptions per hour [2].
What dose of Zepbound is used for sleep apnea versus weight loss?
The dosing ladder is the same for both indications at the start: 2.5 mg injected under the skin once weekly for 4 weeks, then increases in 2.5 mg increments after at least 4 weeks until the maintenance dose is reached [1]. The label says to consider treatment response and tolerability when selecting the maintenance dose [1].
The difference is the maintenance range. For OSA, the label specifies 10 mg or 15 mg once weekly. For weight reduction and long-term maintenance, it is 5 mg, 10 mg, or 15 mg once weekly. The maximum recommended dose for either use is 15 mg once weekly [1].
| Use | Maintenance dosage |
|---|---|
| Obstructive sleep apnea | 10 mg or 15 mg once weekly [1] |
| Weight reduction and long-term maintenance | 5 mg, 10 mg, or 15 mg once weekly [1] |
| Maximum recommended dosage | 15 mg once weekly [1] |
The 2.5 mg dose is a starting dose only, not an approved maintenance dose [4, 5]. The trial’s maximum tolerated dose of 10 mg or 15 mg mirrors the label’s OSA maintenance range [2]. Dose selection and titration are decisions for a prescriber, based on response and tolerability [1].
Zepbound comes as a single-dose pen or single-dose vial in 2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL, and as a KwikPen or multi-dose vial holding four doses each, from 10 mg to 60 mg per 2.4 mL [1].
Can Zepbound replace my CPAP?
The cited trials did not test that. Study 2 participants remained on PAP therapy throughout the trial — the comparison was Zepbound versus placebo added to PAP, not PAP withdrawal [2]. Study 1 participants were people who were unable or unwilling to use PAP in the first place; they were not CPAP users who stopped [2].
Lilly positions Zepbound as a medicine that may help improve OSA in adults with obesity, evaluated with and without PAP therapy [2]. The trial descriptions in these sources include no study in which people with established PAP therapy stopped it. Whether to continue, adjust, or stop PAP therapy is a decision for a treating clinician.
What are the side effects and warnings?
Zepbound carries a boxed warning: in rats, tirzepatide causes thyroid C-cell tumors, and it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans [1]. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, in people with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with known serious hypersensitivity to tirzepatide or its excipients [1]. Symptoms of a possible thyroid tumor to report to a clinician include a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath [2].
The label’s warnings include severe gastrointestinal reactions (not recommended in severe gastroparesis), acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions including anaphylaxis and angioedema, hypoglycemia when used with insulin or an insulin secretagogue, progression of diabetic retinopathy in people with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation [1]. The label instructs patients to inform healthcare providers of any planned surgeries or procedures, and it notes that Zepbound delays gastric emptying and can affect the absorption of oral medicines [1].
The most common adverse reactions, reported in 5% or more of patients, are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease [1]. A KwikPen should never be shared between patients, even with a new needle [1]. Suspected adverse reactions can be reported to Lilly at 1-800-545-5979 or the FDA at 1-800-FDA-1088 [1].
The label has been updated since the OSA approval. The DailyMed version was updated August 28, 2026, with revisions including removal of the Suicidal Behavior and Ideation section (02/2026), revisions to Severe Gastrointestinal Adverse Reactions (02/2026), Diabetic Retinopathy Complications (08/2026), Dosage and Administration (01/2026), and the KwikPen sharing section (01/2026) [1]. FDA’s supplement history shows labeling supplements approved February 25, 2026 and an efficacy-labeling change with clinical data on August 26, 2026 [3].
Will insurance pay for Zepbound for sleep apnea?
Coverage depends on the insurance type and the condition being treated. Lilly’s coverage tool asks which condition a person is seeking coverage for — obesity, overweight with weight-related medical problems, or moderate-to-severe OSA with obesity — because Medicare coverage can vary by condition [4].
For people with commercial insurance that covers Zepbound, the Zepbound Savings Program offers the single-dose pen for as low as $25 per month for up to a 3-month prescription, with terms applying [4, 5].
For people paying out of pocket, LillyDirect lists self-pay program prices for the KwikPen or single-dose vial under the Zepbound Self Pay Journey Program: $299 per month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5, and 15 mg [5, 8]. The $449 tier for the 7.5 mg and higher doses requires refills within 45 days [5].
| Dose | Self-pay program price | Regular price if not refilled within 45 days |
|---|---|---|
| 2.5 mg (starting dose only) | $299/month | — [5] |
| 5 mg | $399/month | — [5] |
| 7.5 mg | $449/month | $499 [5] |
| 10 mg | $449/month | $699 [5] |
| 12.5 mg | $449/month | $699 [5] |
| 15 mg | $449/month | $699 [5] |
Because the OSA maintenance dose is 10 mg or 15 mg, the relevant self-pay tier for sleep apnea treatment is $449 per month with 45-day refills, or $699 per month otherwise [1, 5]. A December 1, 2025 Lilly announcement listed regular non-program prices as $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for 15 mg; the current LillyDirect figures supersede those [8].
These are program prices, not list prices and not insurance. Lilly states the self-pay programs are not insurance, that eligibility is required, that savings are subject to monthly and annual limits, and that a “month” is defined as 28 days [5]. Pen needles for the KwikPen, or needle and syringe for vials, are sold separately [4, 5]. Self-pay vials are available exclusively through LillyDirect [5]. Zepbound may be HSA/FSA eligible, though that varies by plan [4, 5].
Will Medicare’s $50 GLP-1 Bridge cover Zepbound for sleep apnea?
No. The Medicare GLP-1 Bridge, which starts July 1, 2026 and charges $50 per month regardless of income, explicitly excludes people with moderate-to-severe sleep apnea [7]. Its eligibility requirements state: “You don’t have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease.” People with those conditions are told to contact their Medicare drug plan, which may already cover a GLP-1 [7].
The Bridge covers only the Foundayo tablet, Wegovy injection or tablet, and the Zepbound KwikPen — the Zepbound single-dose pen and vials are not covered [7]. Other requirements include Medicare Part D coverage (a standalone drug plan or a Medicare Advantage plan with drug coverage), not already being eligible to receive a GLP-1 through one’s plan, and being at least 18 years old [7]. The BMI criteria are: BMI of 35 or higher; or BMI of 30 or higher with certain heart failure, hard-to-control high blood pressure, or chronic kidney disease stage 3a or above; or BMI of 27 or higher with prediabetes or a prior heart attack, stroke, or blocked arteries in the legs or arms [7].
The $50 payment does not count toward the Part D deductible or the yearly out-of-pocket limit, and these drugs are not eligible for the Medicare Prescription Payment Plan [7]. People whose only coverage is a private fee-for-service plan, a cost contract plan, or PACE are not eligible [7]. Lilly’s own Medicare Bridge messaging is framed for a “Zepbound prescription for weight management,” not OSA [4, 5]. Questions can go to 1-800-MEDICARE (1-800-633-4227), TTY 1-877-486-2048 [7].
What support does Lilly offer for people taking Zepbound for OSA?
Lilly’s Zepbound support pages have separate Weight Management and Obstructive Sleep Apnea tabs, including an OSA-specific Doctor Discussion Guide [6]. A Digital Starter Kit is available by texting “ZB” to 85099 [6]. The Lilly Health app for iOS and Android is free and includes savings card information, dose tracking, and device syncing; Lilly notes it is not a substitute for a clinician [6].
At the approval, Julie Flygare, president and CEO of the patient advocacy group Project Sleep, was quoted urging people to understand OSA symptoms and know that treatments are available, including new options like Zepbound [2]. Lilly’s OSA information page is at zepbound.lilly.com/sleep-apnea [2].
Who is this approval not for?
The approval covers adults with obesity and moderate-to-severe OSA, used with diet and exercise [1]. It does not cover children — safety and effectiveness in children is not known [2]. It does not cover people taking another tirzepatide product or any GLP-1 receptor agonist; the label says coadministration is not recommended [1, 2]. And it does not cover central sleep apnea or OSA without obesity, since the indication is specific to obstructive sleep apnea in adults with obesity [1, 2].
Lilly notes that many cases of OSA go undiagnosed and untreated [2]. Since the label population is adults with moderate-to-severe OSA and obesity, a diagnosis of both conditions precedes any prescription under this indication [1, 2].
Sources
- National Library of Medicine DailyMed. ZEPBOUND (tirzepatide) injection, solution.
- Eli Lilly and Company. FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024.
- US Food and Drug Administration. Drugs@FDA: New Drug Application 217806 (Zepbound, Eli Lilly and Co).
- Eli Lilly and Company. Savings & insurance options | Zepbound (tirzepatide).
- Eli Lilly and Company. Authentic Zepbound (tirzepatide) shipped to you | LillyDirect.
- Eli Lilly and Company. Resources, support, tips & guides | Zepbound (tirzepatide).
- Medicare. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month. July 1, 2026.
- Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. December 1, 2025.
Frequently asked questions
Is Zepbound FDA-approved for sleep apnea, and since when?
Yes. The FDA approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024 [2, 3], through an efficacy supplement for a new indication to NDA 217806. Lilly billed it as the first prescription medicine for this use, and it was Zepbound's second US indication after the November 2023 weight-management approval.
Can Zepbound let me stop using CPAP?
The cited trials did not test that. SURMOUNT-OSA tested Zepbound in people unable or unwilling to use PAP therapy, and separately in people who stayed on PAP for the full year; neither trial took people off established PAP therapy. Whether to change PAP use is a clinician's call.
What dose of Zepbound is used for sleep apnea versus weight loss?
Both uses start at 2.5 mg once weekly for 4 weeks and increase by 2.5 mg after at least 4 weeks. The OSA maintenance dose is 10 mg or 15 mg once weekly; the weight-management maintenance dose is 5 mg, 10 mg, or 15 mg. The maximum is 15 mg, and 2.5 mg is a starting dose only, not a maintenance dose [1, 4, 5].
Do I have to have obesity to get Zepbound for OSA?
Yes. The label indication is to treat moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. It covers obstructive, not central, sleep apnea, and it is not known to be safe or effective in children [1, 2].
How much AHI improvement did trial participants get?
Over 52 weeks, adults not on PAP had 25 fewer breathing disruptions per hour on Zepbound versus 5 on placebo. Adults on PAP had 29 fewer versus 6 on placebo. After one year, 42% of the no-PAP group and 50% of the PAP group reached remission or mild, non-symptomatic OSA, versus 16% and 14% on placebo.
How much weight did people lose in the sleep apnea trial?
Adults on Zepbound without PAP lost an average of 45 lbs, or 18% of body weight, versus 4 lbs (2%) on placebo. Those on Zepbound with PAP lost an average of 50 lbs, or 20%, versus 6 lbs (2%) on placebo. Lilly's summary line is up to 20% weight loss and at least 25 fewer hourly breathing interruptions.
Will Medicare's $50 GLP-1 Bridge cover Zepbound for sleep apnea?
No. The Medicare GLP-1 Bridge, starting July 1, 2026 at $50 per month, requires that you do not have moderate-to-severe sleep apnea (or type 2 diabetes or fatty liver disease). It covers only the Zepbound KwikPen, not the single-dose pen or vials. People with sleep apnea are told to contact their Medicare drug plan, which may already cover a GLP-1.
What does Zepbound cost out of pocket at 10 mg or 15 mg?
Through LillyDirect's self-pay program, the 10 mg and 15 mg KwikPen or vial prices are $449 per month when refilled within 45 days; without the 45-day refill, the regular price is $699 per month. These are program prices, not insurance, with a month defined as 28 days. With commercial insurance that covers Zepbound, the single-dose pen can be as low as $25 per month for up to 3 months [4, 5].
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.